BRZOŇOVÁ, Jana. Development Safety Update Report 2023 CART19. NA. Praha: ÚHKT PRAHA, 2023, 4 pp. NA.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Development Safety Update Report 2023 CART19
Name in Czech Development Safety Update Report 2023 CART19
Authors BRZOŇOVÁ, Jana.
Edition NA. Praha, 4 pp. NA, 2023.
Publisher ÚHKT PRAHA
Other information
Original language English
Type of outcome Research report
Field of Study 30230 Other clinical medicine subjects
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
WWW CART19
Organization unit Faculty of Medicine
Keywords (in Czech) CART19; anti-CD19; chimeric antigen receptor; Acute Lymphoblastic Leukemia;Non-Hodgkin Lymphoma
Keywords in English CART19; anti-CD19; chimeric antigen receptor; Acute Lymphoblastic Leukemia;Non-Hodgkin Lymphoma
Tags interim report, UHKT, user
Tags International impact
Changed by Changed by: Bc. Hana Vladíková, BBA, učo 244692. Changed: 15/1/2024 10:21.
Abstract
Safety and efficacy of anti-CD19 chimeric antigen receptor-modified autologous T cells (CART19) in patients with relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma. A dose escalation, open-Iabel, phase I study. EudraCT 2018-004789-32, ÚHKT-CAR19-01, NCT05054257: Safety and efficacy of anti-CD19 chimeric antigen receptor-modified autologous T cells (CART19) in patients with relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma. A dose escalation, open-Iabel, phase I study. (Principal Investigator: MUDr. Jan Vydra, Ph.D.,
Links
90249, large research infrastructuresName: CZECRIN IV
PrintDisplayed: 17/5/2024 17:42